Table 1 Study and patients’ characteristics
Author, year | Country | Treatment Duration | Intervention | Patients (n) | Age (years) | Male (%) | Baseline HbA1c (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Treatment | Control | Treatment | Control | Treatment | Control | Treatment | Control | Treatment | Control | |||
Shi [34] et al., 2023 | China | 24 weeks | Dapagliflozin 10 mg Once/Daily | Other Antidiabetic Drugs | 40 | 38 | 49.0 | 47.4 | 27 | 27 | 8.38 | 8.66 |
Benedikt [33] et al., 2023 | Austria | 26 weeks | Empagliflozin 10 mg Once/Daily | Placebo Once/Daily | 191 | 183 | 31.0 | 57.0 | 84 | 79 | - | - |
Song [38] et al., 2023 | China | 48 weeks | Dapagliflozin 5 mg Once/Daily | Standard Anti-heart failure Treatment | 46 | 46 | 53.5 | 55.12 | 58.7 | 54.3 | - | - |
Ge [28] et al., 2022 | China | 24 weeks | Dapagliflozin 10 mg Once/Daily | Sacubitril /Valsartan 200 mg Twice/Daily | 60 | 60 | 68.0 | 69.00 | 60 | 48.33 | - | - |
Zhang [32] et al., 2022 | China | 12 weeks | Dapagliflozin 10 mg Once/Daily | Placebo Once/Daily | 28 | 28 | 57.68 | 56.25 | 71.43 | 92.86 | - | - |
Ou [21] et al., 2022 | China | 12 weeks | Liraglutide 0.6 mg + Dapagliflozin 5 mg Once/Daily | Liraglutide 0.6 mg Once/Daily | 68 | 57 | 56.7 | 57.2 | 54.41 | 49.12 | 10.4 | 10.4 |
Koshino [22] et al., 2022 | Netherland | 48 weeks | Canagliflozin 100 + 300 mg Once/Daily | Placebo Once/Daily | 2326 | 1177 | 62.9 | 62.5 | 67 | 67 | 8.2 | 8.2 |
Kobrynska [36] et al., 2022 | Ukraine | 24 weeks | Empagliflozin 10 mg Once/Daily | Metformin | 51 | 49 | - | - | - | - | - | - |
Janić [33] et al., 2022 | Slovenia | 12 weeks | Empagliflozin 25 mg Once/Daily | Placebo Once/Daily | 10 | 10 | 43.1 | 46.0 | - | - | 7.8 | 7.8 |
Huang [29] et al., 2022 | China | 12 weeks | Dapagliflozin 10 mg Once/Daily | Valsartan 80 mg Twice/Daily | 60 | 60 | 56.21 | 55.67 | 56.7 | 60 | 9.31 | 9.31 |
Gohari [27] et al., 2022 | Iran | 26 weeks | Empagliflozin 10 mg Once/Daily | Placebo Once/Daily | 47 | 48 | 62.08 | 63.6 | 48.9 | 33.3 | 8.05 | 7.75 |
Xue [31] et al., 2021 | China | 24 weeks | Dapagliflozin 10 mg Twice/Daily | Conventional anti-diabetic drugs | 35 | 35 | 58.58 | 56.26 | 57.14 | 60 | - | - |
Sposito [37] et al., 2021 | Brazil | 12 weeks | Empagliflozin 10 mg Once/Daily | Glibenclamide 5 mg Once/Daily | 48 | 49 | 57 | 58 | 60 | 61 | 7.9 | 7.9 |
Nandula [24] et al., 2021 | USA | 16 weeks | Canagliflozin 100 mg Once/Daily | Placebo Once/Daily | 15 | 14 | - | - | - | - | - | - |
Bai [26] et al., 2021 | China | 12 weeks | Sitagliptin 100 mg + Dapagliflozin 10 mg Once/Daily | Sitagliptin 100 mg Once/Daily | 40 | 40 | 48.61 | 45.61 | 50 | 55 | - | - |
Kahl [35] et al., 2020 | Germany | 24 weeks | Empagliflozin 25 mg Once/Daily | Placebo Once/Daily | 42 | 42 | 62.7 | 61.5 | 69 | 69 | 6.8 | 6.7 |
Latva-Rasku [30] et al., 2019 | Finland | 8 weeks | Dapagliflozin 10 mg Once/Daily | Placebo Once/Daily | 15 | 16 | 62 | 60 | 86.7 | 75 | 7 | 6.8 |
Garvey [25] et al., 2018 | USA | 52 weeks | Canagliflozin 300 mg Once/Daily | Glimepiride | 100 | 100 | 58.5 | 57.5 | 48 | 55 | 7.8 | 7.7 |